CNCR vs. SBIO

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and SBIO (ALPS Medical Breakthroughs ETF) are both Health & Biotech Equities funds - CNCR tracks the Loncar Cancer Immunotherapy Index while SBIO tracks the S-Network Medical Breakthroughs Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.50%/yr for SBIO.

Performance

CNCR vs. SBIO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

SBIO

• 1D: -4.73%
• 1M: -6.02%
• YTD: -1.78%
• 6M: 5.47%
• 1Y: 67.29%
• 3Y*: 17.25%
• 5Y*: 2.56%
• 10Y*: 7.86%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. SBIO - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
SBIO ALPS Medical Breakthroughs ETF	-1.33%

CNCR vs. SBIO - Sectors Allocation Comparison

Sectors	CNCR	SBIO
Healthcare	96.6%	100.0%
Financial Services	3.3%	-0.0%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

CNCR vs. SBIO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SBIO

SBIO Risk / Return Rank: 74
SBIO Sharpe Ratio Rank: 69
SBIO Sortino Ratio Rank: 68
SBIO Omega Ratio Rank: 60
SBIO Calmar Ratio Rank: 90
SBIO Martin Ratio Rank: 84

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. SBIO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	SBIO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	2.30	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.08	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.24	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.21	—

Drawdowns

CNCR vs. SBIO - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum SBIO drawdown of -63.06%. Use the drawdown chart below to compare losses from any high point for CNCR and SBIO.

Drawdown Indicators

	CNCR	SBIO	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-63.06%	+63.06%
Max Drawdown (1Y) Largest decline over 1 year	—	-12.66%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-42.44%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-53.10%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-63.06%	—
Current Drawdown Current decline from peak	0.00%	-17.95%	+17.95%
Average Drawdown Average peak-to-trough decline	0.00%	-28.45%	+28.45%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	4.15%	—

Volatility

Volatility by Period

	CNCR	SBIO	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	9.94%	—
Volatility (6M) Calculated over the trailing 6-month period	—	22.86%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	29.55%	-29.55%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	33.55%	-33.55%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	33.18%	-33.18%

CNCR vs. SBIO - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than SBIO's 0.50% expense ratio.

Dividends

CNCR vs. SBIO - Dividend Comparison

Neither CNCR nor SBIO has paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SBIO ALPS Medical Breakthroughs ETF	0.00%	0.00%	3.55%	0.22%	0.00%	0.00%	0.00%	0.04%	2.79%	1.77%

Frequently Asked Questions

Which ETF is better, CNCR or SBIO?

On fees, SBIO is cheaper at 0.50% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or SBIO?

SBIO is cheaper with a 0.50% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or SBIO?

CNCR and SBIO have nearly identical dividend yields, around 0.00%.

What is the main difference between CNCR and SBIO?

CNCR tracks Loncar Cancer Immunotherapy Index, while SBIO tracks S-Network Medical Breakthroughs Index. They also come from different issuers: Exchange Traded Concepts and SS&C. Their fees differ too: 0.79% for CNCR and 0.50% for SBIO.